{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T03:26:04.835040+00:00","company":{"ticker":"AQST","cik":1398733,"company_name":"Aquestive Therapeutics, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"debt_financing","fact_key":"8a91a4d07af8760faec34186b95a333c95f9a64b","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-05-13T20:04:40+00:00","payload":{"counterparty":"Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders","effective_date":"2026-05-12","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"three-month SOFR (with a floor of 2.75%) plus 6.25%","item_codes_triggered":["2.03"],"maturity_text":"five years from the closing date","principal_text":"up to $150.0 million"},"claim":"Aquestive Therapeutics, Inc. incurred credit facility of up to $150.0 million with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders at three-month SOFR (with a floor of 2.75%) plus 6.25% maturing five years from the closing date.","evidence_excerpt":"On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”), consisting of a term loan in an aggregate principal amount of $55.0 million that was funded on the Effective Date (the “Tranche A Term Loan”), a term loan in an aggregate principal amount of $20.0 million available subject to certain terms and conditions (the “Tranche B Term Loan”), a term loan in an aggregate principal amount of $25.0 million available subject to certain terms and conditions (the “Tranche C Term Loan”), and a term loan advance available upon the mutual consent of the Lenders and subject to certain terms and conditions in an aggregate principal amount of up to $50.0 million (the “Tranche D Term Loan”), pursuant to a credit agreement and guaranty, dated as of the Effective Date (the “Credit Agreement”), with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agen","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001398733-26-000029","anchor_url":"https://secwatch.observer/filing/0001398733-26-000029#claim-8a91a4d07af8760faec34186b95a333c95f9a64b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/0001398733-26-000029-index.htm"},{"fact_type":"material_agreement","fact_key":"1c79e4472d40b13a017aaebcf1cde9d894121bc2","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-03-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Share Purchase Commitment Agreement","agreement_type":"equity_purchase","counterparty":"certain RTW-affiliated funds","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":"not less than $5,000,000"},"claim":"Aquestive Therapeutics, Inc. entered into Share Purchase Commitment Agreement with certain RTW-affiliated funds valued at not less than $5,000,000 (effective 2026-03-03).","evidence_excerpt":"The Company also entered into a Share Purchase Commitment Agreement with certain RTW-affiliated funds, pursuant to which such funds committed to purchase, in the aggregate, not less than $5,000,000 of Common Stock during the 90-day period following the effective date of the agreement, at prices determined in accordance with Rule 415(a)(4) under the Securities Act.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001398733-26-000016","anchor_url":"https://secwatch.observer/filing/0001398733-26-000016#claim-1c79e4472d40b13a017aaebcf1cde9d894121bc2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm"},{"fact_type":"material_agreement","fact_key":"bf0f71df644f43a43690081e5f795fb0af07ca73","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-03-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Warrant Issuance Agreement","agreement_type":"equity_purchase","counterparty":"funds managed by RTW","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":null},"claim":"Aquestive Therapeutics, Inc. entered into Warrant Issuance Agreement with funds managed by RTW (effective 2026-03-03).","evidence_excerpt":"Concurrently, the Company entered into a Warrant Issuance Agreement with funds managed by RTW pursuant to which the Company agreed to issue a warrant to purchase up to 375,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $4.00 per share, expiring on March 3, 2029.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001398733-26-000016","anchor_url":"https://secwatch.observer/filing/0001398733-26-000016#claim-bf0f71df644f43a43690081e5f795fb0af07ca73","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm"},{"fact_type":"material_agreement","fact_key":"f1238b7b2d2e015960cf25ce300beb2c211525b1","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-03-04T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1 to Purchase and Sale Agreement","agreement_type":"asset_purchase","counterparty":"funds managed by RTW Investments, LP","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":null},"claim":"Aquestive Therapeutics, Inc. amended Amendment No. 1 to Purchase and Sale Agreement with funds managed by RTW Investments, LP (effective 2026-03-03).","evidence_excerpt":"On March 3, 2026, Aquestive Therapeutics, Inc. (the \"Company\") entered into Amendment No. 1 (the \"Amendment\") to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated August 13, 2025, with funds managed by RTW Investments, LP (\"RTW\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001398733-26-000016","anchor_url":"https://secwatch.observer/filing/0001398733-26-000016#claim-f1238b7b2d2e015960cf25ce300beb2c211525b1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm"},{"fact_type":"executive_change","fact_key":"a767328166","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Santo J. Costa resigned as Director at Aquestive Therapeutics, Inc..","evidence_excerpt":"On November 1, 2024, Santo J. Costa, a member of the Board of Directors of Aquestive Therapeutics, Inc. (the “Company”) and the Chairman of the Compensation Committee thereof (the “Compensation Committee”), notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective November 4, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-046223","anchor_url":"https://secwatch.observer/filing/0001628280-24-046223#claim-a767328166","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024046223/0001628280-24-046223-index.htm"},{"fact_type":"executive_change","fact_key":"039350f1b6","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-06-06T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-06-03","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Cassie Jung changed role as Chief Operating Officer at Aquestive Therapeutics, Inc..","evidence_excerpt":"Aquestive Therapeutics, Inc. (the “Company”) has promoted Cassie Jung, 45, to Chief Operating Officer, effective June 3, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-027028","anchor_url":"https://secwatch.observer/filing/0001628280-24-027028#claim-039350f1b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024027028/0001628280-24-027028-index.htm"},{"fact_type":"earnings_release","fact_key":"2ef03a9d6e215c6d82debc00a9f6c31e71574d89","cik":1398733,"ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2024 and provided an update on recent developments in its business.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001628280-24-021110","anchor_url":"https://secwatch.observer/filing/0001628280-24-021110#claim-2ef03a9d6e215c6d82debc00a9f6c31e71574d89","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024021110/0001628280-24-021110-index.htm"}]}